Cuddy Brendan James
European Medicines Agency, Inspections Sector, 7 Westferry Circus, Canary Wharf, London E14 4HB, United Kingdom.
Ann Ist Super Sanita. 2008;44(4):357-8.
The approach of the European Medicines Agency (EMEA) to good laboratory practice (GLP) inspections in the context of authorization of medicinal products is illustrated with particular reference to the EMEA's experience as a receiving authority (RA), the procedures it has in place for the reporting and follow-up of GLP inspections, and the role of the ad hoc GLP inspectors working group. Other key issues dealt with are the relationship between the EU monitoring authorities (MAs) and the EMEA as a specific RA, how inspections outside the EU are handled and some aspects (exchange of information, handling of non-compliance, triggers for inspection) that have been raised during recent inspections.
欧洲药品管理局(EMEA)在药品授权背景下进行良好实验室规范(GLP)检查的方法,将特别参照EMEA作为接收当局(RA)的经验、其针对GLP检查报告及后续跟进所制定的程序,以及特设GLP检查员工作组的作用进行阐述。还将探讨的其他关键问题包括欧盟监管当局(MA)与作为特定RA的EMEA之间的关系、欧盟以外地区检查的处理方式,以及近期检查中出现的一些方面(信息交流、不符合项处理、检查触发因素)。